Low-Dose Nivolumab Plus AVD As Front-Line Therapy for Classical Hodgkin's Lymphoma: Preliminary Results of a Phase 2 Trial

被引：0
作者：
Mateos, Antonio Vega [1 ]
Alfaro, Hector Alejandro Vaquera [1 ]
Vasquez, Ana Cristina Tejada [1 ]
Lopez-Garcia, Yadith Karina [1 ]
Garcia-Salas, Gerardo [1 ]
Cantu, Olga [1 ]
Gomez-De Leon, Andres [1 ]
Gomez-Almaguer, David [1 ]
Tarin-Arzaga, Luz [1 ]
Gutierrez-Aguirre, Cesar Homero [1 ]
Colunga-Pedraza, Perla R. [1 ]
机构：
[1] Univ Autonoma Nuevo Leon, Hosp Univ Dr Jose Eleuterio Gonzalez, Serv Hematol, Monterrey, Mexico
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-208831
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1665 / 1666
页数：2
相关论文
共 50 条
  • [11] A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma
    Hanel, Walter
    Christian, Beth A.
    Maddocks, Kami J.
    Epperla, Narendranath
    William, Basem M.
    Jaglowski, Samantha
    Bond, David A.
    Sawalha, Yazeed
    Reneau, John C.
    Brammer, Jonathan E.
    Baiocchi, Robert
    Blum, Kristie A.
    Alinari, Lapo
    BLOOD, 2020, 136
  • [12] High-dose therapy and ASCT versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy: Long term results
    Carella, A. M.
    Bellei, M.
    Brice, P.
    Gisselbrecht, C.
    Visani, G.
    Colombat, P.
    Fabbiano, F.
    Donelli, A.
    Feugier, P.
    Browett, P.
    Hagberg, H.
    Federico, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 33 - 33
  • [13] Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial
    Kadia, Tapan M.
    Cortes, Jorge
    Ravandi, Farhad
    Jabbour, Elias
    Konopleva, Marina
    Benton, Christopher B.
    Burger, Jan
    Sasaki, Koji
    Borthakur, Gautam
    DiNardo, Courtney D.
    Pemmaraju, Naveen
    Daver, Naval
    Ferrajoli, Alessandra
    Wang, Xuemei
    Patel, Keyur
    Jorgensen, Jeffrey L.
    Wang, Sa
    O'Brien, Susan
    Pierce, Sherry
    Tuttle, Carla
    Estrov, Zeev
    Verstovsek, Srdan
    Garcia-Manero, Guillermo
    Kantarjian, Hagop
    LANCET HAEMATOLOGY, 2018, 5 (09): : E411 - E421
  • [14] Prolonged persistence of SARS-CoV-2 infection during A plus AVD therapy for classical Hodgkin's lymphoma: A case report
    Fujii, Hiroyuki
    Tsuji, Taisuke
    Sugitani, Mio
    Matsumoto, Yosuke
    Yuba, Tatsuya
    Tanaka, Shunya
    Suga, Yoshifumi
    Matsuyama, Aosa
    Goda, Shiho
    Omura, Ayaka
    Shiotsu, Shinsuke
    Takumi, Chieko
    Ono, Seiko
    Hiraoka, Noriya
    CURRENT PROBLEMS IN CANCER, 2021, 45 (06)
  • [15] Phase 3 study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A plus AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL): Echelon-1 study
    Ansell, Stephen Maxted
    Younes, Anas
    Connors, Joseph M.
    Gallamini, Andrea
    Kim, Won Seog
    Friedberg, Jonathan W.
    Feldman, Tatyana A.
    Collins, Graham
    Bartlett, Nancy
    Wang, Jingyuan
    Brady, Kelly
    Sachs, Jessica
    Huebner, Dirk
    Hunder, Naomi N. H.
    Radford, John
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [16] Could cisplatin as a front-line treatment in childhood non-Hodgkin's lymphoma be a promising therapy?
    Papadopoulou, AL
    Moschovi, M
    Panagopoulou-Cristaki, M
    Anagnostou-Keramida, D
    Van Vliet-Constantinidou, C
    Botsonis, A
    Tsangaris, GT
    Tzortzatou-Stathopoulou, F
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 1999, 16 (04) : 341 - 346
  • [17] A randomized, controlled, phase 2 trial of nivolumab plus standard-dose or low-dose bevacizumab for recurrent glioblastoma (NAVAL)
    Ahluwalia, Manmeet Singh
    Peereboom, David M.
    Ozair, Ahmad
    Khosla, Atulya Aman
    Rauf, Yasmeen
    Nayak, Lakshmi
    Ciolfi, Marci
    Alban, Tyler
    Grabowski, Matthew
    Rayman, Pat
    Diaz, Marcella
    Lathia, Justin
    Lee, Eudocia Quant
    Wen, Patrick Y.
    Reardon, David A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [18] High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy: long-term results
    Carella, Angelo Michele
    Bellei, Monica
    Brice, Pauline
    Gisselbrecht, Christian
    Visani, Giuseppe
    Colombat, Philippe
    Fabbiano, Francesco
    Donelli, Amedea
    Luminari, Stefano
    Feugier, Pierre
    Browett, Peter
    Hagberg, Hans
    Federico, Massimo
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (01): : 146 - 148
  • [19] Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial
    Broeckelmann, Paul J.
    Goergen, Helen
    Keller, Ulrich
    Meissner, Julia
    Ordemann, Rainer
    Halbsguth, Teresa V.
    Sasse, Stephanie
    Soekler, Martin
    Kerkhoff, Andrea
    Mathas, Stephan
    Huettmann, Andreas
    Bormann, Matthias
    Zimmermann, Andreas
    Mettler, Jasmin
    Fuchs, Michael
    von Tresckow, Bastian
    Baues, Christian
    Rosenwald, Andreas
    Klapper, Wolfram
    Kobe, Carsten
    Borchmann, Peter
    Engert, Andreas
    JAMA ONCOLOGY, 2020, 6 (06) : 872 - 880
  • [20] Low-Dose Rituximab and High-Dose Dexamethasone As Front-Line Therapy in Adult Patients with Primary Immune Thrombocytopenia
    Gomez-Almaguer, David
    Tarin-Arzaga, Luz C.
    Moreno-Jaime, Brizio
    Jaime-Perez, Jose C.
    Ceballos-Lopez, Adrian A.
    Ruiz-Argueelles, Guillermo J.
    Ruiz-Delgado, Guillermo J.
    Cantu-Rodriguez, Olga
    Gutierrez-Aguirre, Cesar H.
    BLOOD, 2012, 120 (21)
12345